Developing a new class of engineered live bacterial therapeutics to treat human diseases.
Charbonneau MR, Isabella VM, Li N, Kurtz CB. · 2020
Read Developing a new class of engineered live bacterial therapeutics to treat human diseases. by Charbonneau MR, Isabella VM, Li N, Kurtz CB. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7142098.txt.
Description
Charbonneau and co-authors set out how to design medicines made of living, engineered bacteria, in Nature Communications. Microbes in the gut shape metabolic and immune diseases, from obesity to bowel inflammation. Synthetic biology can program harmless bacteria to sense conditions in the body, consume harmful compounds, and deliver therapeutic molecules on site.
The perspective walks through design choices: picking a bacterial chassis, building sensing circuits, and controlling dose and safety. It also covers what regulators and patients will need before such products win acceptance. Engineered strains were already entering clinical trials, including for solid tumors. The authors frame live biotherapeutics as a new drug class with distinct rules.
Catalog record
| CREATOR | Charbonneau MR, Isabella VM, Li N, Kurtz CB. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |